Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02095132
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:33.870929+00:00
Published At
2022-10-05T00:00:00+00:00
Record Updated At
2023-09-26
Results Posted At
2022-10-05
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Central Nervous System Embryonal Tumor With Rhabdoid Features", "Central Nervous System Embryonal Tumor, Not Otherwise Specified", "Central Nervous System Ganglioneuroblastoma", "Embryonal Tumor With Multilayered Rosettes, C19MC-Altered", "Pineoblastoma", "Primary Central Nervous System Neoplasm", "Recurrent Childhood Central Nervous System Embryonal Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Rhabdomyosarcoma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Rhabdomyosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-09-26"
protocolSection.identificationModule.nctId
"NCT02095132"
protocolSection.identificationModule.officialTitle
"A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2022-10-05"

Study condition terms

  • Central Nervous System Embryonal Tumor With Rhabdoid Features (protocolSection.conditionsModule.conditions)
  • Central Nervous System Embryonal Tumor, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
  • Central Nervous System Ganglioneuroblastoma (protocolSection.conditionsModule.conditions)
  • Embryonal Tumor With Multilayered Rosettes, C19MC-Altered (protocolSection.conditionsModule.conditions)
  • Pineoblastoma (protocolSection.conditionsModule.conditions)
  • Primary Central Nervous System Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Childhood Central Nervous System Embryonal Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Medulloblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Neuroblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Rhabdomyosarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Refractory Medulloblastoma (protocolSection.conditionsModule.conditions)
  • Refractory Neuroblastoma (protocolSection.conditionsModule.conditions)
  • Refractory Rhabdomyosarcoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.